1251 related articles for article (PubMed ID: 17001660)
1. In vitro characterization of SLV308 (7-[4-methyl-1-piperazinyl]-2(3H)-benzoxazolone, monohydrochloride): a novel partial dopamine D2 and D3 receptor agonist and serotonin 5-HT1A receptor agonist.
Glennon JC; Van Scharrenburg G; Ronken E; Hesselink MB; Reinders JH; Van Der Neut M; Long SK; Feenstra RW; McCreary AC
Synapse; 2006 Dec; 60(8):599-608. PubMed ID: 17001660
[TBL] [Abstract][Full Text] [Related]
2. An in vivo pharmacological evaluation of pardoprunox (SLV308)--a novel combined dopamine D(2)/D(3) receptor partial agonist and 5-HT(1A) receptor agonist with efficacy in experimental models of Parkinson's disease.
Jones CA; Johnston LC; Jackson MJ; Smith LA; van Scharrenburg G; Rose S; Jenner PG; McCreary AC
Eur Neuropsychopharmacol; 2010 Aug; 20(8):582-93. PubMed ID: 20434890
[TBL] [Abstract][Full Text] [Related]
3. Aplindore (DAB-452), a high affinity selective dopamine D2 receptor partial agonist.
Heinrich JN; Brennan J; Lai MH; Sullivan K; Hornby G; Popiolek M; Jiang LX; Pausch MH; Stack G; Marquis KL; Andree TH
Eur J Pharmacol; 2006 Dec; 552(1-3):36-45. PubMed ID: 17056032
[TBL] [Abstract][Full Text] [Related]
4. S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: I. Cellular, electrophysiological, and neurochemical profile in comparison with ropinirole.
Millan MJ; Cussac D; Gobert A; Lejeune F; Rivet JM; Mannoury La Cour C; Newman-Tancredi A; Peglion JL
J Pharmacol Exp Ther; 2004 Jun; 309(3):903-20. PubMed ID: 14978194
[TBL] [Abstract][Full Text] [Related]
5. Dopamine D2 receptor partial agonists display differential or contrasting characteristics in membrane and cell-based assays of dopamine D2 receptor signaling.
Jordan S; Johnson JL; Regardie K; Chen R; Koprivica V; Tadori Y; Kambayashi J; Kitagawa H; Kikuchi T
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Mar; 31(2):348-56. PubMed ID: 17070976
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo characterization of F-97013-GD, a partial 5-HT1A agonist with antipsychotic- and antiparkinsonian-like properties.
Zazpe A; Artaiz I; Innerárity A; Del Olmo E; Castro E; Labeaga L; Pazos A; Orjales A
Neuropharmacology; 2006 Jul; 51(1):129-40. PubMed ID: 16643965
[TBL] [Abstract][Full Text] [Related]
7. Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile.
Kiss B; Horváth A; Némethy Z; Schmidt E; Laszlovszky I; Bugovics G; Fazekas K; Hornok K; Orosz S; Gyertyán I; Agai-Csongor E; Domány G; Tihanyi K; Adham N; Szombathelyi Z
J Pharmacol Exp Ther; 2010 Apr; 333(1):328-40. PubMed ID: 20093397
[TBL] [Abstract][Full Text] [Related]
8. Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release.
Cosi C; Carilla-Durand E; Assié MB; Ormiere AM; Maraval M; Leduc N; Newman-Tancredi A
Eur J Pharmacol; 2006 Mar; 535(1-3):135-44. PubMed ID: 16554049
[TBL] [Abstract][Full Text] [Related]
9. [3H] A-369508 ([2-[4-(2-cyanophenyl)-1-piperazinyl]-N-(3-methylphenyl) acetamide): an agonist radioligand selective for the dopamine D4 receptor.
Moreland RB; Terranova MA; Chang R; Uchic ME; Matulenko MA; Surber BW; Stewart AO; Brioni JD
Eur J Pharmacol; 2004 Aug; 497(2):147-54. PubMed ID: 15306199
[TBL] [Abstract][Full Text] [Related]
10. Autoradiographic mapping of dopamine-D2/D3 receptor stimulated [35S]GTPgammaS binding in the human brain.
Sóvágó J; Makkai B; Gulyás B; Hall H
Eur J Neurosci; 2005 Jul; 22(1):65-71. PubMed ID: 16029196
[TBL] [Abstract][Full Text] [Related]
11. S 15535, a novel benzodioxopiperazine ligand of serotonin (5-HT)1A receptors: I. Interaction with cloned human (h)5-HT1A, dopamine hD2/hD3 and h alpha2A-adrenergic receptors in relation to modulation of cortical monoamine release and activity in models of potential antidepressant activity.
Millan MJ; Newman-Tancredi A; Rivet JM; Brocco M; Lacroix P; Audinot V; Cistarelli L; Gobert A
J Pharmacol Exp Ther; 1997 Jul; 282(1):132-47. PubMed ID: 9223549
[TBL] [Abstract][Full Text] [Related]
12. Direct activation by dopamine of recombinant human 5-HT1A receptors: comparison with human 5-HT2C and 5-HT3 receptors.
Oz M; Zhang L; Rotondo A; Sun H; Morales M
Synapse; 2003 Dec; 50(4):303-13. PubMed ID: 14556235
[TBL] [Abstract][Full Text] [Related]
13. S 16924 ((R)-2-[1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-Yloxy)-ethyl]-pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: I. Receptorial and neurochemical profile in comparison with clozapine and haloperidol.
Millan MJ; Gobert A; Newman-Tancredi A; Audinot V; Lejeune F; Rivet JM; Cussac D; Nicolas JP; Muller O; Lavielle G
J Pharmacol Exp Ther; 1998 Sep; 286(3):1341-55. PubMed ID: 9732398
[TBL] [Abstract][Full Text] [Related]
14. In vitro profile of the antidepressant candidate OPC-14523 at rat and human 5-HT1A receptors.
Jordan S; Chen R; Koprivica V; Hamilton R; Whitehead RE; Tottori K; Kikuchi T
Eur J Pharmacol; 2005 Jul; 517(3):165-73. PubMed ID: 15985260
[TBL] [Abstract][Full Text] [Related]
15. [35S]Guanosine-5'-O-(3-thio)triphosphate binding as a measure of efficacy at human recombinant dopamine D4.4 receptors: actions of antiparkinsonian and antipsychotic agents.
Newman-Tancredi A; Audinot V; Chaput C; Verrièle L; Millan MJ
J Pharmacol Exp Ther; 1997 Jul; 282(1):181-91. PubMed ID: 9223553
[TBL] [Abstract][Full Text] [Related]
16. Antipsychotics differ in their ability to internalise human dopamine D2S and human serotonin 5-HT1A receptors in HEK293 cells.
Heusler P; Newman-Tancredi A; Loock T; Cussac D
Eur J Pharmacol; 2008 Feb; 581(1-2):37-46. PubMed ID: 18190908
[TBL] [Abstract][Full Text] [Related]
17. Dopamine D2 receptor-mediated G protein activation assessed by agonist-stimulated [35S]guanosine 5'-O-(gamma-thiotriphosphate) binding in rat striatal membranes.
Odagaki Y; Toyoshima R
Prog Neuropsychopharmacol Biol Psychiatry; 2006 Sep; 30(7):1304-12. PubMed ID: 16824659
[TBL] [Abstract][Full Text] [Related]
18. In vivo effects of pardoprunox (SLV308), a partial D₂/D₃ receptor and 5-HT1A receptor agonist, on rat dopamine and serotonin neuronal activity.
Bétry C; Etiévant A; Lambás-Señas L; McCreary AC; Haddjeri N
Synapse; 2011 Oct; 65(10):1042-51. PubMed ID: 21446003
[TBL] [Abstract][Full Text] [Related]
19. Effects of clozapine on rat striatal muscarinic receptors coupled to inhibition of adenylyl cyclase activity and on the human cloned m4 receptor.
Olianas MC; Maullu C; Onali P
Br J Pharmacol; 1997 Oct; 122(3):401-8. PubMed ID: 9351494
[TBL] [Abstract][Full Text] [Related]
20. F15063, a potential antipsychotic with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. I. In vitro receptor affinity and efficacy profile.
Newman-Tancredi A; Assié MB; Martel JC; Cosi C; Slot LB; Palmier C; Rauly-Lestienne I; Colpaert F; Vacher B; Cussac D
Br J Pharmacol; 2007 May; 151(2):237-52. PubMed ID: 17375087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]